MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia

Endometrial Hyperplasia Without Atypia Clinical Trial

Official title:

Medroxyprogesterone Acetate (MPA) Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03675139
• Other study ID #: 53201014
• Status: Completed
• Phase: Phase 3
• Start date: February 26, 2019
• Est. completion date: May 15, 2022

Study information

• Verified date: February 2023
• Source: Fudan University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To compare the efficacy of Medroxyprogesterone Acetate with dydrogesterone in patients having endometrial hyperplasia (EH) without atypia.

Description:

Patients pathologically diagnosed with nonatypical simple or complex EH will be enrolled. Exclusion criteria include malignancy, liver disease or liver tumor (benign or malignant), kidney disease or kidney tumor (benign or malignant), any contradictions against progesterone, history of endometrial atypical hyperplasia or endometrial cancer, any progesterone-dependent tumors, ask for other treatment. A detailed history including menstruation, fertility, other diseases and family history will be collected. Basic information including age, waist circumstances, hip circumstances and blood pressure will also be collected. Blood tests including fasting blood glucose (FBG), postprandial blood glucose (PBG), fasting insulin (FINS), SHBG, sex hormone levels, blood lipids, liver and kidney functions will be performed before taking progesterone orally. All enrolled and consent informed patients will be randomized into two groups, A and B, using computer-generated random numbers. Patients in group A will orally take MPA (Medroxyprogesterone Acetate) (angonghuangtitong, Xianju pharmaceuticals, China)10mg daily from tenth day of menstruation for 15 days for 3-6months. While patients in group B will take dydrogesterone (duphaston; Abbott Healthcare Products B.V, the Netherlands) 10 mg, 2 tablets twice daily from fifth day of menstruation for 20 days for 3-6 months. Endometrial Biopsy (Pipelle) will be performed every 3 months to examine the endometrium. Complete response (CR) is defined as the reversion of EH to proliferative or secretory endometrium; partial response (PR) is defined as regression to disordered proliferative endometrium (DPE) or simple hyperplasia without atypic (only for complex hyperplasia); no response (NR) is defined as the persistence of the disease; and progressive disease (PD) is defined as the progression of endometrial lesions. Another 3-month therapy will be continued if the patients get NR. The longest treatment periods will be 6 months. If the patient gets PD or NR after 6 months therapy, new options must be put. At least 3-month maintenance therapy will be recommended for patients get CR. And all of the enrolled patients will be followed up for 2 years. All data of the therapy, reverse events, side effects, pregnancy and long-term outcomes will be collected.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 471
• Est. completion date: May 15, 2022
• Est. primary completion date: May 14, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Pathologically confirmed diagnosis of endometrial hyperplasia without atypia;
• Consent informed and signed;
• Able to follow treatment and take therapy in Obstetrics and Gynecology of Fudan University

Exclusion Criteria:

• Liver disease or liver tumor (benign or malignant)
• Kidney disease or kidney tumor (benign or malignant)
• Other malignancies in reproductive organs
• Breast cancer or other progesterone-dependent tumors
• History of endometrial atypical hyperplasia or endometrial cancer
• Any contradictions against progesterone
• Under treatment of progestin therapy or oral conceptive drugs one month before enrollment.
• Pregnancy or suspicion of pregnancy
• Ask for other treatment

Related Conditions & MeSH terms

• Endometrial Hyperplasia
• Endometrial Hyperplasia Without Atypia
• Hyperplasia

Intervention

Drug:
• Medroxyprogesterone Acetate
At a dosage of 10mg/day
• Dydrogesterone 10 MG
At a dosage of 20 mg/day

Locations

Country	Name	City	State
China	Obstetrics and Gynecology Hospital, Fudan University	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Xiaojun Chen

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pathological complete response (CR) rates	The CR rates will be calculated after 3 and 6-month therapy based on the following formula: (Number of participants who got CR)/(All enrolled participants). The CR rates will be compared between two therapies (MPA VS dydrogesterone), also between two lesions (SH VS CH).	From date of randomization until the date of CR, assessed up to 6 months
Secondary	Median time of pathological complete response (CR)	Median time of histologic regression from endometrial hyperplasia without atypia to normal endometrium, and comparison will be performed between two treatments and two lesions (SH vs CH).	From date of randomization until the date of CR, assessed up to 6 months
Secondary	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	Adverse events related with MPA (Medroxyprogesterone acetate; ) or dydrogesterone include acne, irregular bleeding, breast tenderness, decreased scalp hair, difficulty falling or remaining asleep, stomach pain, and weight loss or gain, depression and mood changes. Severe side effects include thrombus and impaired liver and kidney function. The investigators will record any symptoms, evaluate the correlation and count the events. And comparison will be performed between two treatments and two lesions (SH vs CH).	up to 2 years after the treatment for each patient
Secondary	Relapse rates	All enrolled patients will be followed up for 2 years. During the following-up period, if patients recur after complete regression, they will be counted and the number of recurrence will be divided by number of patients followed up, then we can get the relapse rates.Comparison will be performed between two treatments and two lesions (SH vs CH).	up to 2 years after the treatment for each patient
Secondary	Rate of pregnancy	For patients have a desire for fertility, pregnancies, births and related outcomes will be counted, and the rate of pregnancy will be counted as number of pregnancies/ number of patients trying to fertility in the following period. Comparison will be performed between two treatments and two lesions (SH vs CH).	up to 2 years after the treatment for each patient
Secondary	Compliance	The investigators designed a questionnaire to evaluate the compliance through treatment. Comparison will be performed between two treatments and two lesions (SH vs CH).	up to 2 years after the treatment for each patient
Secondary	cost	Treatment-related cost in each patient during the period beginning from randomization to the date of CR.Comparison will be performed between two treatments and two lesions (SH vs CH).	From date of randomization until the date of CR, assessed up to 6 months